Clinical Trials Browser

Phase 1 × OTHER × cabozantinib × Clear all

NCT05249114 2026-04-13

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Phase 1 Active not recruiting

Neuroendocrine Tumors

NCT07194044 2026-03-16

METTSEO

Phase 1 Recruiting

Sarcoma, Ewing

NCT06502171 2026-03-12

NF113

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Phase 1 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04878029 2026-01-23

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Phase 1 Recruiting

Carcinoma, Transitional Cell

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT05038839 2025-11-20

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT06132945 2025-11-14

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Phase 1 Active not recruiting

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT06156410 2025-11-14

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Phase 1 Recruiting

Recurrence, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Phase 1 Completed

Metastatic Hormone Refractory Prostate Cancer

NCT05613894 2025-10-31

CaboLu

Phase 1 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07187869 2025-09-23

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Phase 1 Not yet recruiting

Carcinoma, Renal Cell

NCT03611595 2025-08-28

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT04868773 2025-04-16

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Phase 1 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT03299946 2024-09-03

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT03667482 2024-07-23

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Completed

Head and Neck Squamous Cell Cancer

NCT03200587 2024-07-03

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Phase 1 Completed

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04661852 2023-02-15

Cabozantinib With Topotecan-Cyclophosphamide

Phase 1 Completed

Sarcoma, Ewing, Osteosarcoma

NCT04173338 2022-06-14

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase 1 Terminated

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT01574937 2021-08-06

XL-184+Abiraterone in Post-Chemo CRPC

Phase 1 Completed

Prostatic Neoplasms

NCT02008383 2021-02-12

CaboMAb

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01663272 2018-09-19

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Phase 1 Completed

12 enrolled 6 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT01961765 2017-07-21

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01582295 2017-05-25

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Phase 1 Completed

Bone Diseases, Multiple Myeloma

NCT01347788 2016-11-28

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Phase 1 Completed

34 enrolled 6 charts

Prostatic Neoplasms